Expert Opinion on Therapeutic Patents

Papers
(The TQCC of Expert Opinion on Therapeutic Patents is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Malaria transmission blocking compounds: a patent review53
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities45
FAK inhibitors in cancer, a patent review – an update on progress36
Recent developments of agents targeting Vibrio cholerae : patents and literature data35
The role of patent analysis in target selection33
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)32
Update on mGlu4 modulator patents: 2017 to present31
Mucormycosis medications: a patent review30
Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature29
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)28
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)28
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present27
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)26
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review24
Caspase inhibitors: a review on recently patented compounds (2016–2023)23
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)23
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)23
An updated patent review of AKT inhibitors (2020 – present)22
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201322
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)21
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)21
Inhibition of GTPase KRAS G12D : a review of patent literature21
A patent review of MAPK inhibitors (2018 – present)21
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review21
PDE1 inhibitors: a review of the recent patent literature (2008-present)21
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202319
Antiprotozoal drugs: challenges and opportunities19
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)19
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)18
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)17
Small-molecule RNA ligands: a patent review (2018–2024)17
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)16
A patent review of IDH1 inhibitors (2018-present)16
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature16
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)16
An updated patent review on PD-1/PD-L1 antagonists (2022-present)16
An updated patent review of MALT1 inhibitors (2021–present)16
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders16
A patent and literature review of CDK12 inhibitors14
An updated patent review of EZH2 inhibitors (2024–present)13
Antimalarial drugs: what’s new in the patents?13
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)13
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)13
Dopamine D3 receptor ligands: a patent review (2014–2020)13
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)13
Biofilm and bacterial membrane vesicles: recent advances13
A patent review of NLRP3 inhibitors to treat autoimmune diseases12
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)12
An updated patent review on drugs for the treatment of tuberculosis (2018-present)12
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs12
Ferroportin-inhibitor salt: patent evaluation WO201819297312
Biomedical applications of prokaryotic carbonic anhydrases: an update12
Are patents important indicators of innovation for Chagas disease treatment?12
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa11
The patent review of the biological activity of tropane containing compounds11
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)11
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review11
A patent review of mTOR inhibitors for cancer therapy (2011–2020)10
Correction10
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)10
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)10
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity10
An updated patent review of TRPA1 antagonists (2020 – present)10
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)10
Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technology’s stages10
A patent review of selective CDK9 inhibitors in treating cancer10
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents10
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)10
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)10
0.74465394020081